Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET
Moleculin Biotech (Nasdaq: MBRX) has announced a webcast presentation on August 6, 2024, at 8:30 AM ET to discuss plans for its MIRACLE Phase 3 pivotal trial. The trial will evaluate Annamycin in combination with Cytarabine (AnnAraC) for treating AML patients who are refractory to or relapsed after induction therapy. This global trial, including US sites, marks a significant step in Moleculin's clinical development program.
The presentation will feature Walter Klemp, CEO, Dr. Paul Waymack, Senior Chief Medical Officer, and Dr. Michael Andreeff from MD Anderson Cancer Center. Investors can access the webcast via conference call or the company's website.
Moleculin Biotech (Nasdaq: MBRX) ha annunciato una presentazione in webcast il 6 agosto 2024, alle 8:30 AM ET, per discutere i piani del suo MIRACLE Phase 3 trial cruciale. Lo studio valuterà Annamycin in combinazione con Cytarabine (AnnAraC) per il trattamento di pazienti AML che sono refrattari o che hanno avuto una recidiva dopo la terapia di induzione. Questo trial globale, che include siti negli Stati Uniti, segna un passo significativo nel programma di sviluppo clinico di Moleculin.
La presentazione includerà Walter Klemp, CEO, il Dr. Paul Waymack, Chief Medical Officer Senior, e il Dr. Michael Andreeff del MD Anderson Cancer Center. Gli investitori possono accedere al webcast tramite conferenza telefonica o il sito web dell'azienda.
Moleculin Biotech (Nasdaq: MBRX) ha anunciado una presentación en webcast el 6 de agosto de 2024, a las 8:30 AM ET, para discutir los planes de su ensayo pivotal MIRACLE de fase 3. El ensayo evaluará Annamycin en combinación con Cytarabine (AnnAraC) para tratar a pacientes con AML que son refractarios o que han recaído después de la terapia de inducción. Este ensayo global, que incluye sitios en EE. UU., marca un paso significativo en el programa de desarrollo clínico de Moleculin.
La presentación contará con Walter Klemp, CEO, el Dr. Paul Waymack, Chief Medical Officer Senior, y el Dr. Michael Andreeff del MD Anderson Cancer Center. Los inversores pueden acceder al webcast a través de una llamada de conferencia o del sitio web de la empresa.
몰레큘린 바이오텍(Moleculin Biotech, Nasdaq: MBRX)은 2024년 8월 6일 오전 8시 30분(ET)에 MIRACLE 3상 주요 임상 시험에 대한 계획을 논의하기 위한 웹캐스트 발표를 발표했습니다. 이 시험은 유도 치료 후 내성 또는 재발한 AML 환자를 치료하기 위해 Annamycin과 Cytarabine(AnnAraC) 병용 요법의 효과를 평가할 예정입니다. 미국 사이트를 포함한 이 글로벌 시험은 몰레큘린의 임상 개발 프로그램에서 중요한 단계로 자리잡고 있습니다.
발표에는 몰레큘린의 CEO인 월터 클렘프(Walter Klemp), 수석 의료 책임자인 폴 웨이맥(Dr. Paul Waymack), MD 앤더슨 암센터의 마이클 안드리프(Dr. Michael Andreeff)가 참여할 것입니다. 투자자들은 회의 전화를 통해 또는 회사 웹사이트를 통해 웹캐스트에 접속할 수 있습니다.
Moleculin Biotech (Nasdaq: MBRX) a annoncé une présentation en webcast le 6 août 2024 à 8h30 ET pour discuter de ses plans pour l'
La présentation sera animée par Walter Klemp, CEO, le Dr. Paul Waymack, directeur médical senior, et le Dr. Michael Andreeff du MD Anderson Cancer Center. Les investisseurs peuvent accéder au webcast par le biais d'une conférence téléphonique ou via le site web de l'entreprise.
Moleculin Biotech (Nasdaq: MBRX) hat eine Webcast-Präsentation für den 6. August 2024, um 8:30 Uhr ET, angekündigt, um die Pläne für die MIRACLE Phase 3 entscheidende Studie zu besprechen. Die Studie wird Annamycin in Kombination mit Cytarabine (AnnAraC) zur Behandlung von AML-Patienten bewerten, die gegenüber der Induktionstherapie refraktär sind oder einen Rückfall erlitten haben. Diese globale Studie, die Standorte in den USA umfasst, stellt einen bedeutenden Schritt im klinischen Entwicklungsprogramm von Moleculin dar.
In der Präsentation werden Walter Klemp, CEO, Dr. Paul Waymack, Senior Chief Medical Officer, und Dr. Michael Andreeff vom MD Anderson Cancer Center auftreten. Investoren können über einen Konferenzanruf oder die Website des Unternehmens auf den Webcast zugreifen.
- Advancement to Phase 3 pivotal trial for AnnAraC in R/R AML treatment
- Global trial scope, including US sites
- Participation of renowned experts in the webcast presentation
- None.
For the webcast presentation, Walter Klemp, Chairman and Chief Executive Officer, and Dr. Paul Waymack, Senior Chief Medical Officer of Moleculin will be joined by Michael Andreeff, MD, PhD, Professor of Medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Interested participants and investors may access the webcast presentation via conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call or by clicking here. The live audio webcast will be accessible on the Events page of the Investors section of the Moleculin website, moleculin.com, and will be archived for 90 days.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-host-webcast-presentation-to-discuss-recently-announced-plans-for-miracle-phase-3-pivotal-trial-tuesday-august-6-2024-at-830-am-et-302213970.html
SOURCE Moleculin Biotech, Inc.
FAQ
What is the MIRACLE Phase 3 trial for Moleculin Biotech (MBRX)?
When is Moleculin Biotech (MBRX) hosting its webcast presentation on the MIRACLE trial?
Who will be presenting at Moleculin Biotech's (MBRX) MIRACLE trial webcast?
How can investors access Moleculin Biotech's (MBRX) MIRACLE trial webcast?
